PCM
XBI icon

Pennsylvania Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Pennsylvania Capital Management’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,890
Closed -$212K – 143
2020
Q2 		$212K Buy
+1,890
New +$186K 0.11% 109

Other funds holding XBI

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pennsylvania Capital Management's XBI Position: Q3 2020 in Review

Pennsylvania Capital Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2020, closing a stake of 1,890 shares — an estimated $212K sold.

Pennsylvania Capital Management first reported a position in XBI in Q2 2020 and held it in 1 quarter. The position peaked at $212K in Q2 2020. 554 funds tracked by Wall St. Rank hold XBI as of Q3 2020.

  • Pennsylvania Capital Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2020 after selling out during the quarter.
  • Pennsylvania Capital Management sold 1,890 State Street SPDR S&P Biotech ETF shares in Q3 2020, an estimated $212K.
  • Pennsylvania Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 1 quarter.
  • Pennsylvania Capital Management's State Street SPDR S&P Biotech ETF position peaked at $212K in Q2 2020.
  • 554 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2020.

Based on Pennsylvania Capital Management's 13F filing for Q3 2020, filed 7 Oct 2020.